In2it, I would have liked to have known more about it, what the cellular changes were, what organ/tissue it was seen in, etc. But Schering was allowed to proceed with their own ADHD trial using Org-26576 (a Cortex-developed compound from the same period as CX-717), so the FDA was OK with allowing an Ampakine to be dosed longer term. To me it just seemed like the FDA (Psychiatric/Laughren) was prejudiced against Cortex for some reason, plus the FDA was under a lot of pressure at that time to be ultra conservative safety-wise.
As for the a-holes at R+R (Elemer Fudd, et al), who knows what their motivations were. Stoll had previously refused an R+R financing and went with Roth instead, so R+R was ticked at that and put in the .30 cent target as a lesson to other small cap companies. R+R also may have been trying to arrange a buyout on the cheap of Cortex for one of their vulture clients. The artifact was merely the factor that made a distress sale possible.
News 
Market Data 
Discover 
AI
